WO2002019964A3 - Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions - Google Patents

Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions Download PDF

Info

Publication number
WO2002019964A3
WO2002019964A3 PCT/US2001/026658 US0126658W WO0219964A3 WO 2002019964 A3 WO2002019964 A3 WO 2002019964A3 US 0126658 W US0126658 W US 0126658W WO 0219964 A3 WO0219964 A3 WO 0219964A3
Authority
WO
WIPO (PCT)
Prior art keywords
desmethylselegiline
conditions
neoplastic diseases
methods
pharmaceutical compositions
Prior art date
Application number
PCT/US2001/026658
Other languages
French (fr)
Other versions
WO2002019964A2 (en
Inventor
Cheryl D Blume
Anthony R Disanto
Original Assignee
Somerset Pharmaceuticals Inc
Cheryl D Blume
Anthony R Disanto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somerset Pharmaceuticals Inc, Cheryl D Blume, Anthony R Disanto filed Critical Somerset Pharmaceuticals Inc
Priority to CA002420993A priority Critical patent/CA2420993A1/en
Priority to AU8679801A priority patent/AU8679801A/en
Priority to AU2001286798A priority patent/AU2001286798B2/en
Publication of WO2002019964A2 publication Critical patent/WO2002019964A2/en
Publication of WO2002019964A3 publication Critical patent/WO2002019964A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The application is directed to the treatment of neoplastic diseases or conditions by administering R(-) desmethylselegiline, S(+) desmethylselegiline, or a combination of the two. Neoplastic diseases and conditions responsive to R(-) desmethylselegiline and/or S(+) desmethylselegiline include both malignant and benign neoplasms.
PCT/US2001/026658 2000-08-28 2001-08-27 Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions WO2002019964A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002420993A CA2420993A1 (en) 2000-08-28 2001-08-27 Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
AU8679801A AU8679801A (en) 2000-08-28 2001-08-27 Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
AU2001286798A AU2001286798B2 (en) 2000-08-28 2001-08-27 Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22843100P 2000-08-28 2000-08-28
US60/228,431 2000-08-28

Publications (2)

Publication Number Publication Date
WO2002019964A2 WO2002019964A2 (en) 2002-03-14
WO2002019964A3 true WO2002019964A3 (en) 2003-02-27

Family

ID=22857139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/026658 WO2002019964A2 (en) 2000-08-28 2001-08-27 Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions

Country Status (3)

Country Link
AU (2) AU2001286798B2 (en)
CA (1) CA2420993A1 (en)
WO (1) WO2002019964A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1704859B1 (en) * 2005-02-18 2010-08-11 Universitätsklinikum Freiburg Androgen receptor-dependent gene expression control by inhibiting the amine oxidase activity of lysine-specific demethylase (LSD1)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022068A2 (en) * 1995-01-13 1996-07-25 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
WO1999018946A1 (en) * 1997-10-14 1999-04-22 Tatton Nadine A Methods for increasing schwann cell survival
WO1999036076A1 (en) * 1998-01-13 1999-07-22 University Of Saskatchewan Technologies Inc. Composition containing propargylamine for enhancing cancer therapy
WO1999040908A1 (en) * 1998-02-12 1999-08-19 Tatton William G Use of deprenyl compounds to treat viral infections and reduce tissue damage associated therewith
WO1999047133A1 (en) * 1998-03-16 1999-09-23 Somerset Pharmaceuticals, Inc. Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
US6033682A (en) * 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
WO2000071109A2 (en) * 1999-05-21 2000-11-30 Somerset Pharmaceuticals, Inc. Pharmaceutical compositions comprising s-(+) -desmethylselegiline for the treatment of withdrawal
US20010018457A1 (en) * 1995-01-13 2001-08-30 Disanto Anthony R. Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022068A2 (en) * 1995-01-13 1996-07-25 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6033682A (en) * 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US20010018457A1 (en) * 1995-01-13 2001-08-30 Disanto Anthony R. Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms
WO1999018946A1 (en) * 1997-10-14 1999-04-22 Tatton Nadine A Methods for increasing schwann cell survival
WO1999036076A1 (en) * 1998-01-13 1999-07-22 University Of Saskatchewan Technologies Inc. Composition containing propargylamine for enhancing cancer therapy
WO1999040908A1 (en) * 1998-02-12 1999-08-19 Tatton William G Use of deprenyl compounds to treat viral infections and reduce tissue damage associated therewith
WO1999047133A1 (en) * 1998-03-16 1999-09-23 Somerset Pharmaceuticals, Inc. Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
WO2000071109A2 (en) * 1999-05-21 2000-11-30 Somerset Pharmaceuticals, Inc. Pharmaceutical compositions comprising s-(+) -desmethylselegiline for the treatment of withdrawal

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
ANTICANCER RESEARCH. GREECE 1999 NOV-DEC, vol. 19, no. 6B, November 1999 (1999-11-01), pages 5023 - 5028, ISSN: 0250-7005 *
B. SZENDE ET AL.: "APOPTOTIC AND ANTIAPOPTOTIC EFFECT OF (-)DEPRENYL AND (-)DESMETHYL-DEPRENYL ON HUMAN CELL LINES", NEUROBIOLOGY, vol. 8, no. 3-4, 2000, pages 249 - 255, XP001041435 *
B.NICKEL ET AL.: "Effect of selegiline and desmethyl-selegiline on cortical electric activity in rats", J.NEURAL.TRANSM., vol. 32, no. suppl, 1990, pages 139 - 144, XP000579887 *
C.H.WILLIAMS ET AL.: "BIOCHEMICAL AND BEHAVIOURAL STUDIES OF MONOAMINE OXIDASE INHIBITION", IR.J.MED.SCI., vol. 147, no. suppl.1, 1978, pages 71 - 74, XP000579843 *
DATABASE MEDLINE [online] July 1999 (1999-07-01), REUSCH C E ET AL: "The efficacy of L-Deprenyl in dogs with pituitary-dependent hyperadrenocorticism.", XP002211354, Database accession no. NLM10449218 *
DATABASE MEDLINE [online] June 1999 (1999-06-01), THYAGARAJAN S ET AL: "L-deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors.", XP002211358, Database accession no. NLM10484286 *
DATABASE MEDLINE [online] March 1995 (1995-03-01), THYAGARAJAN S ET AL: "Deprenyl reinitiates estrous cycles, reduces serum prolactin, and decreases the incidence of mammary and pituitary tumors in old acyclic rats.", XP002211355, Database accession no. NLM7867565 *
DATABASE MEDLINE [online] November 1999 (1999-11-01), THYAGARAJAN S ET AL: "Inhibition of tumor growth by L-deprenyl involves neural-immune interactions in rats with spontaneously developing mammary tumors.", XP002211359, Database accession no. NLM10697505 *
E.H.HEINONEN ET AL.: "Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of MAO-B in Human Subjects", NEUROLOGY, vol. 43, no. 4Suppl.2, April 1993 (1993-04-01), pages A156, XP000579857 *
E.H.HEINONEN ET AL.: "Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites", CLIN.PHARMACOL.THER., vol. 56, no. 6Pt2, December 1994 (1994-12-01), pages 742 - 749, XP000579881 *
E.H.HEINONEN ET AL.: "Pharmacokinetics and metabolism of selegiline", ACTA NEUROL.SCAND., vol. 126, 1989, pages 93 - 99, XP002014247 *
ENDOCRINE. UNITED STATES JUN 1999, vol. 10, no. 3, June 1999 (1999-06-01), pages 225 - 232, ISSN: 0969-711X *
ENDOCRINOLOGY. UNITED STATES MAR 1995, vol. 136, no. 3, March 1995 (1995-03-01), pages 1103 - 1110, ISSN: 0013-7227 *
H.O.BORBE ET AL.: "Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethyl-selegiline in the rat", J.NEURAL.TRANSM., vol. 32, no. suppl, 1990, pages 131 - 137, XP000579888 *
JOURNAL OF VETERINARY INTERNAL MEDICINE / AMERICAN COLLEGE OF VETERINARY INTERNAL MEDICINE. UNITED STATES 1999 JUL-AUG, vol. 13, no. 4, July 1999 (1999-07-01), pages 291 - 301, ISSN: 0891-6640 *
M.D.GERSHON ET AL.: "MONOAMINE OXIDASE INHIBITION AND THE INDUCTION OF PONTO-GENICULO-OCCIPITAL WAVE ACTIVITY BY RESERPINE IN THE CAT", J. PHARMACOL.EXP.THER., vol. 197, no. 3, 1976, pages 556 - 566, XP000579842 *
P.S. MOHANKUMAR ET AL.: "DEPRENYL STIMULATES THE RELEASE OF LUTEINIZING HORMONE FROM THE PITUITARY IN VITRO", LIFE SCIENCES, vol. 61, no. 18, 1997, pages 1783 - 1788, XP002211353 *
S. THYAGARAJAN ET AL.: "Antitumor effect of L-deprenyl in rats with carcinogen-induced mammary tumors", CANCER LETTERS, vol. 123, 1998, pages 177 - 183, XP002211352 *
W. MARUYUMA ET AL.: "Neuroprotection by (-)-deprenyl and related compounds", MECHANISMS OF AGEING AND DEVELOPMENT, vol. 111, no. 2-3, 1999, pages 189 - 200, XP001104018 *
W.G. TATTON ET AL.: "Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration", NEUROLOGY, vol. 47, no. 6 Suppl. 3, 1996, pages S171 - S183, XP008007306 *
Y.C.MARTIN ET AL.: "Regression Analysis of the Relationship between Physical Properties and the in Vitro Inhibition of Monoamine Oxidase by Propynylamines", J.MED.CHEM., vol. 18, no. 9, 1975, pages 883 - 888, XP000579829 *

Also Published As

Publication number Publication date
WO2002019964A2 (en) 2002-03-14
CA2420993A1 (en) 2002-03-14
AU2001286798B2 (en) 2007-05-17
AU8679801A (en) 2002-03-22

Similar Documents

Publication Publication Date Title
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2002051837A3 (en) Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
WO2001066564A3 (en) Gamma-secretase inhibitors
WO2002034753A3 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
WO2003070163A3 (en) Prostacyclin derivatives for treating cancer
WO2002002506A8 (en) Compounds to treat alzheimer's disease
AU1373499A (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
NZ515392A (en) Respiratory syncytial virus replication inhibitors
TR199701490A2 (en) 3-Hydroxypyridine-2-carbon acidamidester and their manufacture.
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
WO2001024783A3 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
WO2002039953A3 (en) Texaphyrin coordination compounds and uses thereof
WO2002010152A3 (en) Novel indole derivatives and their use as medicaments
EP1440691A3 (en) Treatment of neurotic disorders
HK1048308A1 (en) Novel compounds.
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
DE60026491D1 (en) MELAGATRAN FOR THE TREATMENT OF INFLAMMATION
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
GB0020504D0 (en) Therapeutic method
WO2003018535A3 (en) Novel aminobenzoephenones
WO2002043715A3 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontinence
WO2001060343A3 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
WO2002019964A3 (en) Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2420993

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001286798

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001286798

Country of ref document: AU